KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
Rhea-AI Summary
KALA BIO (NASDAQ: KALA), a clinical-stage biopharmaceutical company focused on developing innovative eye disease therapies, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 5, 2025, at 11:50 a.m. ET in Boston, MA.
The company's management team will deliver the presentation and will be available for one-on-one meetings throughout the day. Interested parties can access the webcast and subsequent recording through the 'Presentations' section on www.kalarx.com.
Positive
- None.
Negative
- None.
News Market Reaction – KALA
On the day this news was published, KALA gained 2.13%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
ARLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the TD Cowen 45th Annual Health Care Conference being held in Boston, MA on Wednesday, March 5, 2025 at 11:50 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, March 5, 2025.
To access the webcast and subsequent archived recording of the presentation, please visit the “Presentations” section of the KALA website at www.kalarx.com.
About KALA BIO, Inc.
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.
Investor Contact:
Taylor Steiner
taylor.steiner@precisionaq.com
212-362-1200
FAQ
When and where is KALA BIO presenting at the TD Cowen Healthcare Conference 2025?
How can investors access KALA BIO's TD Cowen conference presentation?
What type of meetings is KALA BIO offering at the TD Cowen conference?
What is KALA BIO's current business focus in the healthcare sector?
